CDKN2A and cancer: No prognostic significance was found for p16 protein expression in an early-stage CRC cohort (n = 185).<h4>Conclusion</h4>Ribociclib demonstrates significant antitumoral effects across a large panel of cancer cell lines and chemoresistant models, especially in CRC.